COVID-19 Vaccination in Cancer Patients: A Review Article
<p dir="ltr">Coronavirus disease 2019 (COVID-19) infection is caused by severe acute respiratory syndrome coronavirus 2. Adults with cancer are immunocompromised due to several causes including cancer itself and immunosuppressive therapy. Thus, cancer patients are more susceptible to...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513548317622272 |
|---|---|
| author | Rana Mekkawi (18472390) |
| author2 | Bassant A. Elkattan (21348362) Alaaeldin Shablak (14778097) Mohammad Bakr (21348365) Mohamed A. Yassin (8361183) Nabil E. Omar (9545756) |
| author2_role | author author author author author |
| author_facet | Rana Mekkawi (18472390) Bassant A. Elkattan (21348362) Alaaeldin Shablak (14778097) Mohammad Bakr (21348365) Mohamed A. Yassin (8361183) Nabil E. Omar (9545756) |
| author_role | author |
| dc.creator.none.fl_str_mv | Rana Mekkawi (18472390) Bassant A. Elkattan (21348362) Alaaeldin Shablak (14778097) Mohammad Bakr (21348365) Mohamed A. Yassin (8361183) Nabil E. Omar (9545756) |
| dc.date.none.fl_str_mv | 2022-09-06T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1177/10732748221106266 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/COVID-19_Vaccination_in_Cancer_Patients_A_Review_Article/29046161 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Health sciences Public health antiCD20 therapy cancer immunotherapy cellular therapy coronavirus disease 2019 hematologic malignancies hematopoietic stem cell transplantion radiotherapy solid tumors targeted therapy vaccines |
| dc.title.none.fl_str_mv | COVID-19 Vaccination in Cancer Patients: A Review Article |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Coronavirus disease 2019 (COVID-19) infection is caused by severe acute respiratory syndrome coronavirus 2. Adults with cancer are immunocompromised due to several causes including cancer itself and immunosuppressive therapy. Thus, cancer patients are more susceptible to develop COVID-19 infection. As COVID-19 vaccines became available, patients with cancer would benefit from receiving the vaccine. This article aims to review the recent evidences and recommendations about COVID-19 vaccination in cancer patients.</p><p dir="ltr">Current guidelines recommend that patients with cancer should have the priority to receive the vaccine given their immunocompromised state. The timing of administration varies depending on cancer type and treatment. Generally, the vaccine should be given before starting the chemotherapy if possible or in between chemotherapy cycles and away from nadir phase. For other cancer treatments, it is recommended to give the vaccine when there is evidence of blood count recovery. In general, induction therapy and treatment for newly diagnosed patients should not be delayed for the vaccination purpose. It is noteworthy to mention that cancer patients especially those with hematologic malignancies might have absented or attenuated response to the vaccine due to their pathophysiological status.</p><p dir="ltr">On the other hand, the current vaccine guidelines have been criticized for lacking evidence on some important topics that need to be addressed. Firstly, some vaccines have been granted an emergency use authorization, prior to the usual comprehensive safety and efficacy evaluation process. Secondly, specific populations including cancer patients were excluded from the approval trials for safety reasons. Finally, some recommendations regarding the COVID-19 vaccines are extrapolated from other vaccines studies. Further studies are required to fill these gaps and observational studies that include cancer patients are warranted to have a better understanding of the safety and efficacy of the vaccines in cancer patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer Control<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1177/10732748221106266" target="_blank">https://dx.doi.org/10.1177/10732748221106266</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_7e744336fd29d65473c47a92e8718463 |
| identifier_str_mv | 10.1177/10732748221106266 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29046161 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | COVID-19 Vaccination in Cancer Patients: A Review ArticleRana Mekkawi (18472390)Bassant A. Elkattan (21348362)Alaaeldin Shablak (14778097)Mohammad Bakr (21348365)Mohamed A. Yassin (8361183)Nabil E. Omar (9545756)Biomedical and clinical sciencesImmunologyOncology and carcinogenesisPharmacology and pharmaceutical sciencesHealth sciencesPublic healthantiCD20 therapycancer immunotherapycellular therapycoronavirus disease 2019hematologic malignancieshematopoietic stem cell transplantionradiotherapysolid tumorstargeted therapyvaccines<p dir="ltr">Coronavirus disease 2019 (COVID-19) infection is caused by severe acute respiratory syndrome coronavirus 2. Adults with cancer are immunocompromised due to several causes including cancer itself and immunosuppressive therapy. Thus, cancer patients are more susceptible to develop COVID-19 infection. As COVID-19 vaccines became available, patients with cancer would benefit from receiving the vaccine. This article aims to review the recent evidences and recommendations about COVID-19 vaccination in cancer patients.</p><p dir="ltr">Current guidelines recommend that patients with cancer should have the priority to receive the vaccine given their immunocompromised state. The timing of administration varies depending on cancer type and treatment. Generally, the vaccine should be given before starting the chemotherapy if possible or in between chemotherapy cycles and away from nadir phase. For other cancer treatments, it is recommended to give the vaccine when there is evidence of blood count recovery. In general, induction therapy and treatment for newly diagnosed patients should not be delayed for the vaccination purpose. It is noteworthy to mention that cancer patients especially those with hematologic malignancies might have absented or attenuated response to the vaccine due to their pathophysiological status.</p><p dir="ltr">On the other hand, the current vaccine guidelines have been criticized for lacking evidence on some important topics that need to be addressed. Firstly, some vaccines have been granted an emergency use authorization, prior to the usual comprehensive safety and efficacy evaluation process. Secondly, specific populations including cancer patients were excluded from the approval trials for safety reasons. Finally, some recommendations regarding the COVID-19 vaccines are extrapolated from other vaccines studies. Further studies are required to fill these gaps and observational studies that include cancer patients are warranted to have a better understanding of the safety and efficacy of the vaccines in cancer patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer Control<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1177/10732748221106266" target="_blank">https://dx.doi.org/10.1177/10732748221106266</a></p>2022-09-06T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1177/10732748221106266https://figshare.com/articles/journal_contribution/COVID-19_Vaccination_in_Cancer_Patients_A_Review_Article/29046161CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/290461612022-09-06T03:00:00Z |
| spellingShingle | COVID-19 Vaccination in Cancer Patients: A Review Article Rana Mekkawi (18472390) Biomedical and clinical sciences Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Health sciences Public health antiCD20 therapy cancer immunotherapy cellular therapy coronavirus disease 2019 hematologic malignancies hematopoietic stem cell transplantion radiotherapy solid tumors targeted therapy vaccines |
| status_str | publishedVersion |
| title | COVID-19 Vaccination in Cancer Patients: A Review Article |
| title_full | COVID-19 Vaccination in Cancer Patients: A Review Article |
| title_fullStr | COVID-19 Vaccination in Cancer Patients: A Review Article |
| title_full_unstemmed | COVID-19 Vaccination in Cancer Patients: A Review Article |
| title_short | COVID-19 Vaccination in Cancer Patients: A Review Article |
| title_sort | COVID-19 Vaccination in Cancer Patients: A Review Article |
| topic | Biomedical and clinical sciences Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Health sciences Public health antiCD20 therapy cancer immunotherapy cellular therapy coronavirus disease 2019 hematologic malignancies hematopoietic stem cell transplantion radiotherapy solid tumors targeted therapy vaccines |